Mp32-01 oncological outcomes in patients with metastatic urothelial carcinoma after discontinuing pembrolizumab as a second-line treatment: a retrospective multicenter real-world cohort study

You have accessJournal of UrologyCME1 Apr 2023MP32-01 ONCOLOGICAL OUTCOMES IN PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA AFTER DISCONTINUING PEMBROLIZUMAB AS A SECOND-LINE TREATMENT: A RETROSPECTIVE MULTICENTER REAL-WORLD COHORT STUDY Toyohiro Yamada, Risa Tomioka, Tomohiro Yokoyama, Fumiya Sugino, Naoya Kumada, Shinichi Takeuchi, Makoto Kawase, Manabu Takai, Daiki Kato, Koji Iinuma, Keita Nakane, and Takuya Koie Toyohiro YamadaToyohiro Yamada More articles by this author , Risa TomiokaRisa Tomioka More articles by this author , Tomohiro YokoyamaTomohiro Yokoyama More articles by this author , Fumiya SuginoFumiya Sugino More articles by this author , Naoya KumadaNaoya Kumada More articles by this author , Shinichi TakeuchiShinichi Takeuchi More articles by this author , Makoto KawaseMakoto Kawase More articles by this author , Manabu TakaiManabu Takai More articles by this author , Daiki KatoDaiki Kato More articles by this author , Koji IinumaKoji Iinuma More articles by this author , Keita NakaneKeita Nakane More articles by this author , and Takuya KoieTakuya Koie More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003265.01AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: The treatment options are currently limited, and the oncological outcomes remain unclear for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. METHODS: This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. RESULTS: The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p<0.001). The median progression-free survival (PFS) times were four months in the BSC group and 14 months in the treatment group (p<0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. CONCLUSIONS: Third-line therapy may have clinical potential advantages to improve the oncological outcomes in patients with mUC.Further prospective studies and long-term evaluations in large patient populations are required to identify the useful predictive markers for determining patients with mUC who should continue pembrolizumab treatment for a relatively long term. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e439 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Toyohiro Yamada More articles by this author Risa Tomioka More articles by this author Tomohiro Yokoyama More articles by this author Fumiya Sugino More articles by this author Naoya Kumada More articles by this author Shinichi Takeuchi More articles by this author Makoto Kawase More articles by this author Manabu Takai More articles by this author Daiki Kato More articles by this author Koji Iinuma More articles by this author Keita Nakane More articles by this author Takuya Koie More articles by this author Expand All Advertisement PDF downloadLoading ...